科研之友
微信
新浪微博
Facebook
分享链接
摘要
Superparamagnetic iron oxide (SPIO) nanoparticles are primarily used as contrast agents in magnetic resonance imaging. SPIO have also been derivatized to add targeting and drug-carrier functionality as drug delivery devices. The preparation and characterization of amino-functionalized SPIO (ASPIO) and lactose-derivatized galactose-terminal-ASPIO are now reported. The target for galactose-terminal-ASPIO is the cell-surface asialoglycoprotein receptor (ASGPR) expressed by hepatocytes. Two batches of ASPIO with average particle sizes of 61 1421 nm and 127 11251 nm [full-width half maximum; FWHMI were prepared. The small ASPIO increased from 61 nm to 278 [3091 nm upon lactosylation (Gal-ASPIO-278) and to 302 [2801 by N-acetylation (NAcASPIO-302); the larger ASPIO afforded galactosyl-terminal ASPIO of 337 [3721 nm and N-acetylated ASPIO of 326 [3081 nm. The LD50 of Gal-ASP10-278 was 1500 I.Lg/mL to HepG2 cells; Gal-ASPIO-278 associated with HepG2 cells in vitro, whereas NAcSPIO-302, prepared from the same ASPIC) batch, did not. Gal-ASP10-278 and NAcASP10-302 were not bound by ASPGR non-expressing 143B cells. The association of Gal-ASPIO-278 to HepG2 cells was reduced by free galactose, supporting the model of ASGPR-mediated binding. These data underline the potential application of Gal-ASPIO as a targeted ligand for ASPGR-expressing cells in vivo. (D 2008 Elsevier B.V.
- 出版日期2008-8-6
